Keywords: zyrtec, continues, drive, ucb, pharma, belgian, drugs
Zyrtec continues to drive UCB pharma
Article | 17 February 2003
Belgian drugs and chemicals company UCB has reported sales of 1.48billion euros ($1.59 billion) for its pharmaceutical operations for full-year 2002, a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
